2SMOLEN JS, LANDEWE R, BREEDVELD FC, et ol. EULARrecommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs[J]. Ann Rheum Dis, 2010, 69(6): 964-975.
3BRENNAN FM, MCINNES IB. Evidence that cytokines play a role in rheumatoid arthritis[J]. J Clin Invest, 2008, 118 (11): 3537-3545.
4SMOLEN JS, ALETAHA D, KOELLER M, et al. New therapies for treatment of rheumatoid arthritis[j]. Lancet, 2007, 370(9602) : 1861-1874.
8COMBE B, LANDEWE R, LUKAS C, et al. EULAR recom- mendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)[J]. Ann Rheum Dis, 2007, 66(1): 34-45.
9RUPERTO N, LOVELL DJ, CUTTICA R, et all. Long-term ef- ficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension[l]. Ann Rheum Dis, 2010, 69(4): 718-722.
10SENOLT L, VENCOVSKY J, PAVELKA K, et ol. Prospective new biological therapies for rheumatoid arthritis[J]. Autoimmun Rev, 2009, 9(2): 102-107.
